Why the study?
Does finerenone slow kidney disease progression and reduce cardiovascular risk in people with non-diabetic chronic kidney disease?
Does finerenone slow kidney disease progression and reduce cardiovascular risk in people with non-diabetic chronic kidney disease?
Answers are grounded in this paper and cite their sources.
Finerenone may have a broader role in nephrology practice by slowing kidney disease progression and reducing cardiovascular risk in non-diabetic CKD.
New trial evidence suggests that finerenone may slow kidney disease progression and reduce cardiovascular risk in people with non-diabetic chronic kidney disease, including those with glomerular disease. These findings raise the possibility of a broader future role for finerenone in nephrology practice.
No takes yet. Share an insight, caveat, or question.
Peter Ellis (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: